Mark Sabag - 05 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: Executive Vice President, International Markets Commercial
Issuer ticker: TEVA
Reported as of: 05 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Mar 2026, 16:23:23 UTC
Prior SEC filing: 06 Mar 2026
Next SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag

Key filing fact

Mark Sabag filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 09 Mar 2026.

Key facts

This page summarizes Mark Sabag's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Mar 2026, 16:23.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721442 Primary reporting owner

Sabag Mark

Relationship: Executive Vice President, International Markets Commercial
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +15,723
Change %: +5.8%
Price
Shares after: 287,042
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -15,723
Change %: -25%
Price: $0.000000^*
Shares after: 47,170
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 15,723
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.

SEC remarks

Executive Vice President, International Markets Commercial